Advertisement

Minerva Neurosciences, Inc. NERV

Set alert

Price alert · NERV

All alert types
2.32 USD +0.08 +3.57%

At close · Oct 30

2.32 0.00 0.00%

After hours · Oct 30, 5:23 PM ET

Bid
2.31 × 2
Ask
2.32 × 2
1.96 Day range 2.32
2.20 52-week range 8.07
YTD
-42.29%
1 year
-42.57%
Open
2.27
Prev close
2.24
Mkt cap
110.77M
Vol
394.69K
Avg vol
182.52K
EPS
-36.12
P/E
0.00
Div yield
0.00%
More statistics
Low
1.96
High
2.32
Forward P/E
-0.79
Beta
0.17
Short ratio
0.41
Inst. own
30.47%
Dividend
0.00
Ex-div date
50-d avg
2.33
200-d avg
2.67
1y target
5.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 5, 2024Earnings: 2.97; estimate -1.01; surprise 394.06%
  • Nov 6, 2024Rating: HC Wainwright & Co. · Neutral → Neutral
Signals (100)
NameDateAgo
MACD: Buy SignalOct 28, 20264 days ago
RSI: OversoldOct 21, 20261 week ago
MACD: Sell SignalOct 12, 20262 weeks ago
RSI: OversoldOct 12, 20262 weeks ago
MACD: Buy SignalOct 6, 20263 weeks ago
SMA: BearishSep 4, 20261 month ago
SMA: BullishSep 3, 20261 month ago
MACD: Sell SignalSep 2, 20262 months ago
SMA: BearishSep 1, 20262 months ago
SMA: BearishAug 28, 20262 months ago
SMA: BullishAug 26, 20262 months ago
SMA: BullishAug 18, 20262 months ago
SMA: BearishAug 17, 20262 months ago
SMA: BullishAug 14, 20262 months ago
SMA: BearishAug 11, 20262 months ago
SMA: BullishAug 10, 20262 months ago
MACD: Buy SignalAug 5, 20262 months ago
MACD: Sell SignalJul 24, 20263 months ago
MACD: Buy SignalJul 23, 20263 months ago
MACD: Sell SignalJul 13, 20263 months ago
SMA: BearishJul 7, 20263 months ago
SMA: BearishJul 1, 20264 months ago
SMA: BullishJun 29, 20264 months ago
SMA: BullishJun 29, 20264 months ago
MACD: Buy SignalJun 22, 20264 months ago
MACD: Sell SignalJun 15, 20264 months ago
MACD: Buy SignalJun 5, 20264 months ago
SMA: BullishMay 20, 20265 months ago
SMA: BearishMay 19, 20265 months ago
RSI: OversoldMay 18, 20265 months ago
MACD: Sell SignalMay 1, 20266 months ago
SMA: BearishApr 27, 20266 months ago
SMA: BullishApr 17, 20266 months ago
MACD: Buy SignalApr 16, 20266 months ago
SMA: BearishMar 30, 20267 months ago
MACD: Sell SignalMar 20, 20267 months ago
MACD: Buy SignalMar 9, 20267 months ago
RSI: OverboughtMar 9, 20267 months ago
MACD: Sell SignalMar 5, 20268 months ago
MACD: Buy SignalFeb 27, 20268 months ago
RSI: OverboughtFeb 27, 20268 months ago
MACD: Sell SignalFeb 26, 20268 months ago
RSI: OverboughtFeb 10, 20268 months ago
SMA: BullishFeb 2, 20269 months ago
MACD: Buy SignalFeb 2, 20269 months ago
SMA: BearishJan 30, 20269 months ago
SMA: BullishJan 26, 20269 months ago
SMA: BearishJan 22, 20269 months ago
MACD: Sell SignalJan 20, 20269 months ago
SMA: BullishJan 5, 202610 months ago
MACD: Buy SignalJan 5, 202610 months ago
MACD: Sell SignalJan 2, 202610 months ago
SMA: BearishDec 31, 202510 months ago
MACD: Buy SignalDec 19, 202510 months ago
SMA: BullishDec 18, 202510 months ago
MACD: Sell SignalDec 18, 202510 months ago
SMA: BearishDec 17, 202510 months ago
MACD: Buy SignalDec 15, 202510 months ago
SMA: BullishDec 4, 202511 months ago
SMA: BearishDec 2, 202511 months ago
MACD: Sell SignalNov 3, 202512 months ago
RSI: OverboughtOct 21, 20251 year ago
RSI: OverboughtOct 8, 20251 year ago
MACD: Buy SignalOct 7, 20251 year ago
SMA: BullishOct 6, 20251 year ago
SMA: BearishSep 29, 20251 year ago
SMA: BullishSep 24, 20251 year ago
SMA: BearishSep 18, 20251 year ago
MACD: Sell SignalSep 4, 20251 year ago
RSI: OverboughtAug 18, 20251 year ago
SMA: BullishAug 15, 20251 year ago
MACD: Buy SignalAug 15, 20251 year ago
SMA: BearishAug 7, 20251 year ago
MACD: Sell SignalJul 31, 20251 year ago
RSI: OverboughtJul 16, 20251 year ago
MACD: Buy SignalJul 15, 20251 year ago
SMA: BullishJul 11, 20251 year ago
SMA: BearishJul 10, 20251 year ago
SMA: BullishJul 9, 20251 year ago
SMA: BearishJul 3, 20251 year ago
SMA: BullishJul 2, 20251 year ago
SMA: BearishJul 1, 20251 year ago
MACD: Sell SignalJun 26, 20251 year ago
SMA: BullishJun 3, 20251 year ago
MACD: Buy SignalMay 30, 20251 year ago
MACD: Sell SignalMay 7, 20251 year ago
SMA: BearishMay 6, 20251 year ago
SMA: BullishApr 22, 20251 year ago
MACD: Buy SignalApr 16, 20251 year ago
MACD: Sell SignalApr 3, 20251 year ago
MACD: Buy SignalMar 12, 20251 year ago
RSI: OversoldFeb 28, 20251 year ago
SMA: BearishFeb 7, 20251 year ago
MACD: Sell SignalFeb 7, 20251 year ago
RSI: OverboughtJan 28, 20251 year ago
SMA: BullishJan 27, 20251 year ago
MACD: Buy SignalJan 27, 20251 year ago
MACD: Sell SignalJan 13, 20251 year ago
MACD: Buy SignalDec 26, 20241 year ago
MACD: Sell SignalDec 20, 20241 year ago

Key statistics

Market cap
14.83M
Enterprise value
48.58M
Trailing P/E
0.00
Forward P/E
-0.79
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
EPS (TTM)
-0.45
Beta
0.17
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-16.77M
Total cash
26.53M
Total debt
60.00M
Return on equity
0.00%
Shares outstanding
6.99M
Short % of float
0.23%
50-day average
2.33
200-day average
2.67

Analyst view

Consensus: none

Price target (mean) 5.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -1.05.

Earnings history

Financials — quick view

All financials
NERV Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NERV Net income — quarterly 17.47M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NERV EPS — quarterly 0.36
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

NERV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2024Sep 1, 2024-1.012.97+3.98+394.06%
Aug 6, 2024Jun 1, 2024-0.97-1.09-0.12-12.37%
May 1, 2024Mar 1, 2024-1.20-1.13+0.07+5.83%
Feb 22, 2024Dec 1, 2023-0.88-1.19-0.31-35.23%
Nov 7, 2023Sep 1, 2023-0.77-1.03-0.26-33.77%
Aug 1, 2023Jun 1, 2023-0.44-1.12-0.68-154.55%

Upgrades / downgrades

NERV analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2024HC Wainwright & Co.reitNeutralNeutral
Aug 7, 2024HC Wainwright & Co.mainNeutralNeutral
May 2, 2024HC Wainwright & Co.mainNeutralNeutral
Feb 27, 2024HC Wainwright & Co.reitNeutralNeutral
Aug 2, 2023HC Wainwright & Co.mainNeutralNeutral
May 16, 2023HC Wainwright & Co.reitNeutralNeutral

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on NERV — it syncs with the Stock Master app.

Insider holders

NERV insider holders
InsiderRelationLatest transactionDateShares held
AHLHOLM FREDERICK WChief Financial OfficerSaleApr 30, 202317,518
LUTHRINGER REMYChief Executive OfficerSaleMay 1, 2023184,819
RACE GEOFFREYPresidentSaleApr 30, 202351,324

Institution ownership

NERV institution ownership
Holder% heldSharesValueReported
Federated Hermes, Inc.19.32%1,351,2752.86MSep 29, 2024
Vanguard Group Inc3.60%252,060534.37KSep 29, 2024
Renaissance Technologies, LLC2.25%157,200333.26KSep 29, 2024
O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC)1.53%107,256227.38KSep 29, 2024
Blackrock Inc.1.04%72,669154.06KSep 29, 2024
Geode Capital Management, LLC0.81%56,456119.69KSep 29, 2024

Fund ownership

NERV fund ownership
Holder% heldSharesValueReported
Federated Hermes Kaufmann Fund11.91%833,0001.77MJul 30, 2024
Federated Hermes Kaufmann Small Cap Fund9.95%696,1501.48MJul 30, 2024
Vanguard Total Stock Market Index Fund2.51%175,805372.71KSep 29, 2024
Vanguard Extended Market Index Fund1.06%74,257157.42KSep 29, 2024
Fidelity Extended Market Index Fund0.43%30,07363.75KOct 30, 2024
Federated Hermes Kaufmann Fund II0.25%17,22536.52KSep 29, 2024
Advertisement